DRMA
Dermata Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−1.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +17.8%
- EBIT
- +18.4%
- EPS
- +90.6%
- Free cash flow
- +25.7%
- Operating cash flow
- +26.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +86.7%
- EPS
- +59.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +36.7%
- EBIT
- +37.9%
- Net income
- +38.5%
- EPS
- +89.8%
- Free cash flow
- +30.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026